Mironid is an innovative new Scottish drug discovery company that produces and supplies high value pre-clinical drug development candidates to the pharmaceutical industry.
The Company’s novel approach to lead generation enables the identification, design and optimisation of hit compounds into proprietary high quality drug candidate molecules with first in class or best in class therapeutic potential in disease indications with a large unmet medical need.
Mironid is building and progressing a pipeline of early stage drug discovery programmes aimed at identifying subtype selective inhibitors and modulators of PDE4 enzymes that will generate novel and differentiated therapies for a range of therapeutic indications in areas such as:
- Chronic inflammatory diseases (e.g. psoriatic arthritis and chronic obstructive pulmonary disease).
- Autosomal dominant polycystic kidney disease.
- Haematological and solid cancers (e.g. prostate cancer).
Our Management Team:
The Company was founded by Prof Miles Houslay (CSO) and has established a high calibre multidisciplinary board and management team with a strong combination of industrial and applied academic experience, further supported by highly experienced advisors, to drive delivery of the Company’s objectives.